oprelvekin
Sign in to saveAlso known as Neumega, AGIF, IL-11, Adipogenesis inhibitory factor, Interleukin-11 precursor
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.
Research
71 papers- Oprelvekin.2012
- Oprelvekin. Genetics Institute.Current opinion in investigational drugs (London, England : 2000) · 2001
- Oprelvekin-associated bilateral optic disk edema.American journal of ophthalmology · 2005
- Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.Journal of the American Pharmaceutical Association (Washington, D.C. : 1996) · 1999
- Oprelvekin: an alternative treatment for thrombocytopenia.Clinical journal of oncology nursing · 1999
via PubMed
Wikidata facts
- Has use
- medication
Show 3 more facts
- defined daily dose
- 3.5
- subject has role
- antineoplastic
- has characteristic
- biopharmaceutical
Sources (3)
via Wikidata · CC0
~10 min read
Encyclopedic overview
11 sectionsContents
- Chemical, pharmacological and marketing data
- Indications
- Contraindications and precautions
- Pregnancy
- Lactation
- Side effects
- Interactions
- Necessary examinations during treatment
- Dosage regimen
- Additional information
- References
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.
==Chemical, pharmacological and marketing data== IL-11 is a member of a family of human growth factors and is being produced in the bone marrow of healthy adults. Synonyms are: AGIF Adipogenesis inhibitory factor Interleukin-11 precursor.
Excerpted from Wikipedia’s “oprelvekin” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0